节点文献

从研究者角度谈Ⅰ期临床试验健康受试者的管理和权益保护

Management and rights/interests protection of healthy subjects from perspective of investigators in phase Ⅰ clinical trial

  • 推荐 CAJ下载
  • PDF下载
  • 不支持迅雷等下载工具,请取消加速工具后下载。

【作者】 贾晶莹胡朝英刘烨李婷婷宋蓉周沁逸王奕君徐霄琰余琛

【Author】 JIA Jing-ying;HU Chao-ying;LIU Ye;LI Ting-ting;SONG Rong;ZHOU Qin-yi;WANG Yi-jun;XU Xiao-yan;YU Chen;Central Laboratory, Shanghai Clinical Center, Chinese Academy of Sciences/Shanghai Xuhui Central Hospital;

【机构】 中国科学院上海临床研究中心/上海市徐汇区中心医院中心实验室

【摘要】 Ⅰ期临床试验是药物临床研究的起始阶段,是整个药物研发链中十分重要的一环。Ⅰ期临床试验通常是以健康受试者为主要研究对象的单中心临床研究,健康受试者不但不能获得疾病治疗的益处,还常常需要承受高剂量试验药物所引起的不良反应。对Ⅰ期临床试验受试者的保护应贯穿在试验的整个过程中,从方案设计、伦理审查和知情同意、保险和研究协议、身份识别和个人信息保护、临床观察及安全性评价等方面进行严格管理。

【Abstract】 As a very important part of the whole drug development chain, phase Ⅰ clinical trial is the initial stage of drug clinical research. Healthy subjects are usually recruited by a single site for a special phaseⅠ clinical study. The healthy subjects could not obtain treatment benefits as patients, instead they often endure the adverse reactions caused by the high dose of investigational medicinal product. The protection for phase Ⅰclinical trial subjects should be run through the whole process from protocol design, ethics review and informed consent, insurance and study contract, identity recognition and personal information protection, clinical observation and safety evaluation, all of which need to be strictly managed.

【基金】 上海市徐汇区青年人才培养计划资助项目(RCKT201205)
  • 【文献出处】 中国新药与临床杂志 ,Chinese Journal of New Drugs and Clinical Remedies , 编辑部邮箱 ,2015年02期
  • 【分类号】R95
  • 【被引频次】10
  • 【下载频次】427
节点文献中: 

本文链接的文献网络图示:

本文的引文网络